Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Depressive disorder is known as being accompanied with the activation of immune system which
could lead to a series of changes including the neuron apoptosis, synapses transmission
inhibition and emotional symptoms. The activation of protein kinase C (PKC) can reverse the
immune/inflammatory process and restore the neuroplasticity and neurotransmitters
transmission. Based on our finding that patients with major depressive disorder (MDD) showed
a significantly lower gene expression of PRKCB1, while the PKC activation mediated by PRKCB1,
we hypothesize that PRKCB1 contribute to the development of MDD and treatment response by its
specific expression in brain, regulating ERBB, Chemokine signaling pathways and PKC
activation during the neuroinflammatory process. In the present study, we aim to evaluate and
verify the regulation effect of PRKCB1 on the neuroimmune and inflammatory mechanism in
depressive disorder by a serious of studies focus on PRKCB1 gene expression modulating
process and different downstream biomarkers which associated with PRKCB1 effect, combined
with the specified treatment (plus omega-3 poly unsaturated fat acids). This study may
provide scientific evidences for using neuroinflammatory biomarkers to diagnose MDD, as well
as personalized treatment.